These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 12684909)

  • 21. Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C.
    Kobayashi M; Suzuki F; Akuta N; Suzuki Y; Arase Y; Ikeda K; Hosaka T; Sezaki H; Kobayashi M; Iwasaki S; Sato J; Watahiki S; Miyakawa Y; Kumada H
    J Med Virol; 2006 Oct; 78(10):1276-83. PubMed ID: 16927289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term follow-up of chronic hepatitis B after the emergence of mutations in the hepatitis B virus polymerase region.
    Natsuizaka M; Hige S; Ono Y; Ogawa K; Nakanishi M; Chuma M; Yoshida S; Asaka M
    J Viral Hepat; 2005 Mar; 12(2):154-9. PubMed ID: 15720530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A study on efficacy of lamivudine therapy in decompensated cirrhosis of liver due to chronic hepatitis B virus infection.
    Sharma YR; Miah AR; Saha SK; Mohammed S; Rahman M; Roy PK; Hasan M
    Nepal Med Coll J; 2004 Dec; 6(2):106-11. PubMed ID: 16295739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Severe acute exacerbation of chronic hepatitis B: a unique presentation of a common disease.
    Wong VW; Chan HL
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1179-86. PubMed ID: 19682192
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An outbreak of fulminant hepatitis B in immunocompromised hemodialysis patients.
    Igaki N; Nakaji M; Moriguchi R; Akiyama H; Tamada F; Oimomi M; Goto T
    J Gastroenterol; 2003; 38(10):968-76. PubMed ID: 14614604
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long-term lamivudine therapy for hepatitis B e antigen-positive chronic hepatitis B.
    Tsubota A; Arase Y; Suzuki F; Kobayashi M; Matsuda M; Sato J; Suzuki Y; Akuta N; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kumada H
    J Med Virol; 2004 May; 73(1):7-12. PubMed ID: 15042641
    [TBL] [Abstract][Full Text] [Related]  

  • 27. YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine.
    Matsuda M; Suzuki F; Suzuki Y; Tsubota A; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Satoh J; Kobayashi M; Ikeda K; Miyakawa Y; Kumada H
    J Med Virol; 2004 Oct; 74(2):361-6. PubMed ID: 15332287
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Viral load speaks little about toll on liver.
    Mahtab MA; Rahman S; Khan M; Kamal M; Mamun AA; Karim MF
    Hepatobiliary Pancreat Dis Int; 2007 Oct; 6(5):483-6. PubMed ID: 17897910
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis E virus as an etiology of acute exacerbation of previously unrecognized asymptomatic patients with hepatitis B virus-related chronic liver disease.
    Kumar M; Sharma BC; Sarin SK
    J Gastroenterol Hepatol; 2008 Jun; 23(6):883-7. PubMed ID: 18070014
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Viral features of lamivudine resistant hepatitis B genotypes A and D.
    Zöllner B; Petersen J; Puchhammer-Stöckl E; Kletzmayr J; Sterneck M; Fischer L; Schröter M; Laufs R; Feucht HH
    Hepatology; 2004 Jan; 39(1):42-50. PubMed ID: 14752821
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HBe antigen loss during lamivudine therapy is not caused by mutations in precore and core promoter genes in patients with chronic hepatitis B.
    Suzuki F; Tsubota A; Arase Y; Suzuki Y; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Satoh J; Takagi K; Kumada H
    J Med Virol; 2003 Jul; 70(3):355-60. PubMed ID: 12766997
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels.
    Tseng TC; Liu CJ; Wang CC; Chen PJ; Lai MY; Chen DS; Kao JH
    Antivir Ther; 2009; 14(2):203-10. PubMed ID: 19430095
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stopping lamivudine therapy after biochemical breakthrough may be a feasible option in selected HBeAg-positive patients.
    Jang JW; Choi JY; Bae SH; Yoon SK; Kim CW; Nam SW; Lee CD; Lee YS; Cha SB; Chung KW
    J Med Virol; 2005 Nov; 77(3):367-73. PubMed ID: 16173025
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive factors for early HBeAg seroconversion in acute exacerbation of patients with HBeAg-positive chronic hepatitis B.
    Kim HS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
    Gastroenterology; 2009 Feb; 136(2):505-12. PubMed ID: 19101558
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The impact of HBeAg positivity/negativity and HBV DNA loads on the prognosis of chronic severe hepatitis B].
    Sun QF; Lü Y; Xu DZ; Lan XY; Liu JY; Sun XJ
    Zhonghua Gan Zang Bing Za Zhi; 2006 Jun; 14(6):410-3. PubMed ID: 16792862
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Predictive factors of hepatitis B virus DNA negative conversion among patients with chronic hepatitis B during lamivudine therapy].
    Chen JL; Wang L; Yan J; Zhang L; Yu H; Fan XL
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Sep; 21(3):273-5. PubMed ID: 17971944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease.
    Yuen MF; Seto WK; Chow DH; Tsui K; Wong DK; Ngai VW; Wong BC; Fung J; Yuen JC; Lai CL
    Antivir Ther; 2007; 12(8):1295-303. PubMed ID: 18240869
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evolution of hepatitis B virus precore/basal core promoter gene in HBeAg-positive chronic hepatitis B patients receiving lamivudine therapy.
    Lin CL; Liao LY; Wang CS; Chen PJ; Lai MY; Chen DS; Kao JH
    Liver Int; 2004 Feb; 24(1):9-15. PubMed ID: 15101995
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Relationship between HBV DNA serum level and acute exacerbation of the disease in chronic hepatitis B patients].
    Zhou X; Gao Z; Yao J
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1999 Dec; 13(4):335-9. PubMed ID: 12759971
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine.
    Di Marco V; Marzano A; Lampertico P; Andreone P; Santantonio T; Almasio PL; Rizzetto M; Craxì A;
    Hepatology; 2004 Oct; 40(4):883-91. PubMed ID: 15382125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.